Signatera™ exceeds 100 peer-reviewed publications, further validating our MRD leadership

Signatera™ exceeds 100 peer-reviewed publications, further validating our MRD leadership

Oncology

Natera is committed to oncology patients by optimizing therapy decisions from diagnosis to survivorship with actionable answers:

Tumor-informed, molecular residual disease (MRD) assessment and treatment response monitoring
Comprehensive genomic profiling to identify clinically relevant DNA & RNA biomarkers and can be run on the same sample as the MRD assay
Hereditary cancer testing includes commonly screened-for genes associated with 12+ types of cancer

Natera Oncology Portfolio

Watch now to learn more about Natera’s oncology suite of products.

Our Tests

Signatera - is cancer lurking?

Use Signatera ctDNA testing after surgery to evaluate the need for adjuvant chemotherapy and avoid unnecessary treatment.
Use Signatera to detect recurrence earlier while it may still be resectable, and reduce false positives.
Use Signatera during immunotherapy treatment to help evaluate treatment response.

Colorectal Cancer
Immunotherapy Monitoring
Bladder Cancer
Breast Cancer
Lung Cancer
Skin Cancers
Gynecologic Cancers

Altera – are there more treatment options?

Use Altera tumor genomic profiling to find more treatment options for cancer based on the tumor’s somatic profile.
Use Altera to discover potential clinical trials for patients with somatic mutations.
Order Altera with Signatera to get both tests from just one tissue.

Learn more

Empower – can we target a germline mutation in treatment?

Use Empower to uncover germline (hereditary) mutations fast with our STAT testing option.
Use Empower to understand why cancer might be common in the family.

Learn more